LifeMD (NASDAQ:LFMD) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

LifeMD (NASDAQ:LFMD) posted its quarterly earnings data on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03, FiscalAI reports. LifeMD had a net margin of 0.10% and a negative return on equity of 168.23%. The company had revenue of $44.63 million for the quarter, compared to analyst estimates of $48.80 million.

Here are the key takeaways from LifeMD’s conference call:

• Third-quarter revenue was $44.6 million, below guidance of $48 million–$51 million and down about 7% year over year. LifeMD cut its 2026 revenue outlook to $188 million–$191 million from $205.5 million–$212.5 million and now expects an adjusted EBITDA loss of $10.6 million–$12.6 million.
• LifeMD finalized arrangements with Eli Lilly and Novo Nordisk to fulfill and ship branded GLP-1 medications through its pharmacy, potentially adding revenue and gross profit dollars from prescriptions it previously fulfilled through third parties. Management cautioned that gross margin percentage will decline as branded-drug revenue is reported on a gross basis.
• Management said customer acquisition cost fell 40% from its June peak, while the share of new Weight Management patients choosing multi-month plans rose from about 25% to 85%. Active subscribers were up 13% year over year and nearly flat sequentially despite a 34% quarter-over-quarter reduction in selling and marketing expense.
• The AT&T collaboration is live in 11 states, reaching about 29 million customers, with nationwide rollout expected in January; the company also plans to market its enterprise offering to employers. Management described these as lower-cost growth opportunities, but said they were not included in fourth-quarter guidance and will report traction as they scale.
• LifeMD ended the quarter with $21.9 million in cash and no debt, then closed a $12.5 million term loan to support working-capital needs. It is targeting a 25% reduction in operating expenses by the first quarter of 2027 and said it expects roughly 30% revenue and patient growth in 2027 on about the same fixed overhead.

LifeMD Price Performance

LifeMD stock traded down $0.12 during mid-day trading on Thursday, reaching $1.66. The company had a trading volume of 1,629,100 shares, compared to its average volume of 876,691. The company has a 50 day moving average of $2.65 and a 200-day moving average of $3.59. LifeMD has a 52 week low of $1.60 and a 52 week high of $5.38.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on LFMD. BTIG Research decreased their price target on LifeMD from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Wall Street Zen downgraded shares of LifeMD from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. KeyCorp set a $5.00 price objective on LifeMD and gave the stock an “overweight” rating in a research report on Friday, August 7th. B. Riley Financial initiated coverage on LifeMD in a research report on Friday, September 11th. They set a “buy” rating and a $8.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of LifeMD in a research report on Monday, November 2nd. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $7.57.

About LifeMD

LifeMD, Inc. is a direct-to-consumer telehealth company that provides virtual medical care, prescription treatments and related health services through its digital platform. The company connects patients with licensed health care providers for online consultations, ongoing care and, when clinically appropriate, prescription medications. Its services include virtual primary care and programs focused on areas such as weight management, men’s health, women’s health, dermatology and chronic-care support.